Quarterly report pursuant to Section 13 or 15(d)

Business Acquisition - Intangible assets acquired and liabilities assumed based on the fair values (Details)

v3.23.3
Business Acquisition - Intangible assets acquired and liabilities assumed based on the fair values (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Common Stock Value $ 122 $ 16
Preferred stock value 0 $ 0
TeraImmune [Member]    
Business Acquisition [Line Items]    
Common Stock Value 476  
Contingent consideration 118  
Total consideration paid 9,702  
TeraImmune [Member] | Equity Option [Member] | Restricted Stock [Member]    
Business Acquisition [Line Items]    
Total consideration paid 68  
TeraImmune [Member] | Series X Non-Voting Convertible Preferred Stock [Member]    
Business Acquisition [Line Items]    
Preferred stock value $ 9,040